Participation of Somatic Stem Cells, Labeled by a Unique Antibody (A3) Recognizing both N-glycan and Peptide, to Hair Follicle Cycle and Cutaneous Wound Healing in Rats.

Chisa Katou-Ichikawa,Hironobu Nishina,Takeshi Izawa,Mitsuru Kuwamura,Miyuu Tanaka,Jyoji Yamate,Shigeo Takenaka

doi:10.3390/ijms21113806

Chisa Katou-Ichikawa, Hironobu Nishina + Show 5 more

Open Access

https://doi.org/10.3390/ijms21113806

Copy DOI

Abstract

A monoclonal antibody (A3) was generated by using rat malignant fibrous histiocytoma (MFH) cells as the antigen. Generally, MFH is considered to be a sarcoma derived from undifferentiated mesenchymal cells. Molecular biological analyses using the lysate of rat MFH cells revealed that A3 is a conformation specific antibody recognizing both N-glycan and peptide. A3-labeled cells in bone marrow were regarded as somatic stem cells, because the cells partly coexpressed CD90 and CD105 (both immature mesenchymal markers). In the hair follicle cycle, particularly the anagen, the immature epithelial cells (suprabasal cells) near the bulge and some immature mesenchymal cells in the disassembling dermal papilla and regenerating connective tissue sheath/hair papilla reacted to A3. In the cutaneous wound-healing process, A3-labeled epithelial cells participated in re-epithelialization in the wound bed, and apparently, the labeled cells were derived from the hair bulge; in addition, A3-labeled immature mesenchymal cells in the connective tissue sheath of hair follicles at the wound edge showed the expansion of the A3 immunolabeling. A3-labeled immature epithelial and mesenchymal cells contributed to morphogenesis in the hair cycle and tissue repair after a cutaneous wound. A3 could become a unique antibody to identify somatic stem cells capable of differentiating both epithelial and mesenchymal cells in rat tissues.

Highlights

Monoclonal antibody is an indispensable tool for biological science, as well as the medical field, for regenerative therapy
Some antibodies recognizing the cluster of the differentiation (CD) 34, CD90 and stage-specific-embryonic antigen (SSEA) have been used for identification of stem cells, because epitopes are expressed in immature cells in the body [2]
We developed a unique monoclonal antibody; A3 was generated by using rat malignant fibrous histiocytoma (MFH)-derived cultured cells as the antigen [3]

Summary

Introduction

Monoclonal antibody is an indispensable tool for biological science, as well as the medical field, for regenerative therapy If such antibody has high specific antigen capable of recognizing a certain epitope that may regulate cellular functions such as cell differentiation, survival and death, immunohistochemistry with the antibody is useful to identify cells expressing the epitope [1]. Some antibodies recognizing the cluster of the differentiation (CD) 34, CD90 and stage-specific-embryonic antigen (SSEA) have been used for identification of stem cells, because epitopes are expressed in immature cells in the body [2]. These antibodies should be useful for studies on the stem cell niche. Based on the gene expression profiling, functional analysis and histopathological findings of MFHs, it has been considered that MFH may be derived from mesenchymal stem cells or undifferentiated mesenchymal cells; human MFH is called pleomorphic undifferentiated sarcoma [4]

Methods

Results

Discussion

Conclusion